Masking drug treatments in the Cardiac Arrhythmia Pilot Study (CAPS). FASHP for the CAPS Investigators.
The effectiveness of masking in the Cardiac Arrhythmia Suppression Study (CAPS) was assessed by surveying investigators and study coordinators. CAPS patients were assigned one of five treatments: encainide, flecainide, imipramine, moricizine, or placebo. Had all treatments appeared identical and equal numbers of patients been assigned to each, 20% of guesses of treatment assignment would be correct by chance alone. Since neither was possible in CAPS, higher rates of correct guessing were expected. Overall, respondents correctly identified treatment 39% of the time. Investigators identified the drug 30% of the time with rates of 20%, 24%, 37%, 20%, and 55% for the five treatment groups, respectively, whereas coordinators identified the treatments 47% of the time with scores of 42%, 45%, 50%, 40%, and 60%. Side effects and a suboptimal masking design detracted from masking; electrocardiographic changes did not imipramine, which caused characteristic side effects, was the most frequently identified active treatment. Scores were higher for investigators who had prior experience with the drugs, but scores did not improve over the course of the trial. Findings suggest that to improve masking all drugs should have been matched in appearance or persons evaluating treatments should not have been allowed to see the drugs.
VA Cooperative Studies Program.
C
C
Haakenson
T
T
Akiyama
A
A
Hallstrom
M R
MR
Sather
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D015982:Bias; D002986:Clinical Trials as Topic / Q000379:methods*; D004311:Double-Blind Method; D004341:Drug Evaluation / Q000379:methods*; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications; D010865:Pilot Projects; D010919:Placebos; D012107:Research Design
D000889:Anti-Arrhythmia Agents; D010919:Placebos